Non-alcoholic fatty liver disease. Other diseases of liver
Conditions
Interventions
Sponsors
Vice chancellor for Research, Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients who agree to participate in the study; Women aged 20-50 years (premenopausal) and in men 20-65 years; Patients newly diagnosed. Exclusion criteria: Alcohol intake; Any cause of chronic liver disease other than NAFLD, such as testing positive for hepatitis B, hepatitis C and autoimmune hepatitis – Immune; Suffering from gastrointestinal disease, diabetes and rheumatoid arthritis; Presence of inherited Hemochromatosis (transferrin saturation greater than 45%) and Wilson's disease; Cholestatic liver disease, advanced liver disease, heart failure, thyroid (abnormal TSH) and renal disease; History of cancer and treatment; Receiving supplements of vitamins (A,C,E), antioxidants, fiber and omega-3 within 3 weeks before baseline and during the study; Drugs such as corticosteroids, amiodarone, tamoxifen, cyclins, perhexiline, methotrexate, aspirin and hydralazine; Presence of pregnancy or lactation or menopause; Taking contraceptive drugs; Liver transplantation; Gastric bypass surgery; Performing a complete intravenous feeding; Rapid weight loss; Cut part of the intestine and gastropathy; Follow the diet and weight loss, Cachexia and Taking anticoagulation.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver Enzymes(ALT,AST). Timepoint: At baseine and after 4 weeks of intervention. Method of measurement: Autoanalyzer.;Total Cholesterol. Timepoint: At baseine and after 4 weeks of intervention. Method of measurement: Spectrophotometry.;Triglyceride. Timepoint: At baseine and after 4 weeks of intervention. Method of measurement: Spectrophotometry.;HDL. Timepoint: At baseine and after 4 weeks of intervention. Method of measurement: Spectrophotometry.;LDL. Timepoint: At baseine and after 4 weeks of intervention. Method of measurement: Friedewald Formula.;Insulin. Timepoint: At baseine and after 4 weeks of intervention. Method of measurement: ELIZA.;HOMA-IR. Timepoint: At baseine and after 4 weeks of intervention. Method of measurement: Formula.;Fasting Blood Sugar. Timepoint: At baseine and after 4 weeks of intervention. Method of measurement: Spectrophotometry.;AST/ALT. Timepoint: At baseine and after 4 weeks of intervention. Method of measurement: Formula.;Pentraxin 3. Timepoint: At baseine and after 4 weeks of intervention. Method of measurement: ELIZA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Food intake. Timepoint: At baseine and after 4 weeks of intervention. Method of measurement: dietary record questionnaire.;Body Mass Index. Timepoint: At baseine and after 4 weeks of intervention. Method of measurement: Scales and meters. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed